Business Wire

Adversaries Continue Cyberattack Onslaught with Greater Precision and Innovative Attack Methods according to 1H2022 NETSCOUT DDoS Threat Intelligence Report

27.9.2022 13:05:00 EEST | Business Wire | Press release

Share

NETSCOUT SYSTEMS, INC. (NASDAQ: NTCT) today announced findings from its 1H2022 DDoS Threat Intelligence Report. The findings demonstrate how sophisticated cybercriminals have become at bypassing defenses with new DDoS attack vectors and successful methodologies.

"By constantly innovating and adapting, attackers are designing new, more effective DDoS attack vectors or doubling down on existing effective methodologies," said Richard Hummel, threat intelligence lead, NETSCOUT. "In the first half of 2022, attackers conducted more pre-attack reconnaissance, exercised a new attack vector called TP240 PhoneHome, created a tsunami of TCP flooding attacks, and rapidly expanded high-powered botnets to plague network-connected resources. In addition, bad actors have openly embraced online aggression with high-profile DDoS attack campaigns related to geopolitical unrest, which have had global implications."

Deployed in most of the world's ISPs, large data centers, and government and enterprise networks, NETSCOUT Arbor DDoS attack protection solutions send anonymized DDoS attack statistics to NETSCOUT's Active Level Threat Analysis System (ATLAS™). This data, which includes visibility into more than 190 countries, 550 industries, and 50,000 autonomous system numbers (ASNs), is then analyzed and curated by NETSCOUT's ATLAS Security Engineering and Response Team (ASERT) to provide unique insights in the report. No other vendor sees and knows more about DDoS attack activity and best practices in protection than NETSCOUT.

Key findings from the 1H2022 NETSCOUT DDoS Threat Intelligence Report include:

  • There were 6,019,888 global DDoS attacks in 1st half of 2022.
  • TCP-based flood attacks (SYN, ACK, RST) remain the most used attack vector, with approximately 46% of all attacks continuing a trend that started in early 2021.
  • DNS water-torture attacks accelerated into 2022 with a 46% increase primarily using UDP query floods, while carpet-bombing attacks experienced a big comeback toward the end of the second quarter; overall, DNS amplification attacks decreased by 31% from 2H2021 to 1H2022.
  • The new TP240 PhoneHome reflection/amplifications DDoS vector was discovered in early 2022 with a record-breaking amplification ratio of 4,293,967,296:1; swift actions eradicated the abusable nature of this service.
  • Malware botnet proliferation grew at an alarming rate, with 21,226 nodes tracked in the first quarter to 488,381 nodes in the second, resulting in more direct-path, application-layer attacks.

Geopolitical Unrest Spawns Increased DDoS Attacks
As Russian ground troops entered Ukraine in late February, there was a significant uptick in DDoS attacks targeting governmental departments, online media organizations, financial firms, hosting providers, and cryptocurrency-related firms, as previously documented. However, the ripple effect resulting from the war had a dramatic impact on DDoS attacks in other countries too, including:

  • Ireland experienced a surge in attacks after providing service to Ukrainian organizations.
  • India experienced a measurable increase in DDoS attacks following its abstention from the UN Security Council and General Assembly votes condemning Russia's actions in Ukraine.
  • On the same day, Taiwan endured its single-highest number of DDoS attacks after making public statements supporting Ukraine, as with Belize.
  • Finland experienced a 258% increase in DDoS attacks year-over-year, coinciding with its announcement to apply for NATO membership.
  • Poland, Romania, Lithuania, and Norway were targeted by DDoS attacks linked to Killnet; a group of online attackers aligned with Russia.
  • While the frequency and severity of DDoS attacks in North America remained relatively consistent, satellite telecommunications providers experienced an increase in high-impact DDoS attacks, especially after providing support for Ukraine's communications infrastructure.
  • Russia experienced a nearly 3X increase in daily DDoS attacks since the conflict with Ukraine began and continued through the end of the reporting period.

Similarly, as tensions between Taiwan, China, and Hong Kong escalated in 1H2022, DDoS attacks against Taiwan regularly occurred in concert with related public events.

NETSCOUT's DDoS Threat Intelligence Report covers the latest trends and activities in the DDoS threat landscape. It covers data captured from NETSCOUT's ATLAS and expert insights from ASERT.

The visibility and insights compiled from the global DDOS attack data, represented in the DDoS Threat Intelligence Report, and seen in the Omnis Threat Horizon portal, fuel the ATLAS Intelligence Feed (AIF). In addition, AIF continuously arms NETSCOUT's Omnis and Arbor security portfolio enabling them to automatically detect and block threat activity for enterprises and service providers worldwide.

Visit our interactive website for more information on NETSCOUT's semi-annual DDoS Threat Intelligence Report. You can also find us on Facebook, LinkedIn , and Twitter for threat updates and the latest trends and insights.

About NETSCOUT
NETSCOUT SYSTEMS, INC. (NASDAQ: NTCT) protects the connected world from cyberattacks and performance disruptions through advanced network detection and response and pervasive network visibility. Powered by our pioneering deep packet inspection at scale, we serve the world's largest enterprises, service providers, and public sector organizations. Learn more at www.netscout.com or follow @NETSCOUT on LinkedIn, Twitter, or Facebook.

©2022 NETSCOUT SYSTEMS, INC. All rights reserved. NETSCOUT, the NETSCOUT logo, Guardians of the Connected World, Adaptive Service Intelligence, Arbor, ATLAS, Cyber Threat Horizon, InfiniStream, nGenius, nGeniusONE, and Omnis are registered trademarks or trademarks of NETSCOUT SYSTEMS, INC., and/or its subsidiaries and/or affiliates in the USA and/or other countries. Third-party trademarks mentioned are the property of their respective owners.

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

Contact information

Editorial Contacts:

Maribel Lopez
Manager, Marketing & Corporate Communications
+1 781 362 4330
maribel.lopez@netscout.com

Chris Shattuck
Finn Partners for NETSCOUT
+1 678 504 6785
NETSCOUT-US@FinnPartners.com

About Business Wire

For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Phase 3 RAINIER Results Supporting Best-in-Class Potential of Povetacicept in IgA Nephropathy Published in the New England Journal of Medicine and Presented at the American Society of Nephrology Kidney Week 202623.10.2026 20:42:00 EEST | Press release

Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced the publication of Phase 3 RAINIER results for povetacicept in the New England Journal of Medicine (NEJM), presentation of these data at the American Society of Nephrology (ASN) Kidney Week 2026 in Denver, Colorado, and advancement of the povetacicept clinical research program in IgAN. Vertex will also host an investor event during ASN on October 23 at 6:15-7 p.m. MDT (8:15-9 p.m. EDT). Further details are below. Data being presented include a pre-specified Week 36 interim analysis of the ongoing Phase 3 RAINIER trial of povetacicept, an engineered fusion protein and dual inhibitor of the BAFF (B cell activating factor) and APRIL (a proliferation inducing ligand) cytokines, in immunoglobulin A nephropathy (IgAN). RAINIER met its primary endpoint, with povetacicept achieving a 52.0% reduction from baseline in proteinuria at Week 36 and a statistically significant and clinically meaningful 49.8% reduction versus placebo (

Lifezone Metals Confirms Advanced Negotiations with Orion CMC on Kabanga Nickel Project23.10.2026 17:19:00 EEST | Press release

Lifezone Metals Limited (NYSE: LZM) notes comments made today by Oskar Lewnowski, Founder and Group Chief Executive of Orion Resource Partners, in an interview with Bloomberg Television regarding the Company’s Kabanga Nickel Project in Tanzania. In response to inbound inquiries from media outlets and investors following the interview, the Company can confirm that negotiations with Orion Critical Mineral Consortium (Orion CMC) regarding a significant equity investment into the Kabanga Nickel Project are at an advanced stage. The Orion CMC is a global investment platform launched by Orion Resource Partners in partnership with the U.S. International Development Finance Corporation (DFC) and Abu Dhabi's sovereign investor ADQ. As previously announced, the Company has been running a competitive process, led by Standard Chartered Bank, to secure a strategic investment into the Kabanga Nickel Project. Social Media LinkedIn | X | YouTube About Lifezone Metals Lifezone Metals (NYSE: LZM) is com

BeOne Medicines Reports Sustained Survival Benefit with TEVIMBRA-ZIIHERA Combination in First-Line HER2+ Gastroesophageal Cancer23.10.2026 17:15:00 EEST | Press release

BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new survival results from the planned second interim analysis (IA2) and final formal analysis of the Phase 3 HERIZON-GEA-01 trial, further confirming the benefit of TEVIMBRA® (tislelizumab) plus ZIIHERA® (zanidatamab) and chemotherapy as first-line treatment for patients with HER2-positive locally advanced or metastatic gastroesophageal adenocarcinoma (GEA). The results will be presented today as a late-breaking abstract during a rapid oral session at the European Society for Medical Oncology (ESMO) Congress 2026 in Madrid, Spain (LBA79). Mark Lanasa, M.D., Ph.D., Chief Medical Officer, Solid Tumors at BeOne, said: “Following the U.S. approval in August, these longer-term data provide further evidence supporting TEVIMBRA plus ZIIHERA and chemotherapy as the new standard of care in all first-line HER2-positive advanced gastroesophageal adenocarcinoma patients, regardless of PD-L1 sta

inDrive and Pony.ai Announce Collaboration to Explore Autonomous Mobility in Kazakhstan Built on NVIDIA Hyperion23.10.2026 16:00:00 EEST | Press release

inDrive, the global mobility and delivery platform, today announced it has signed a memorandum of understanding (MOU) with NVIDIA and Pony.ai, a global leader in the large-scale commercialization of autonomous driving technology, to explore the future of autonomous ride-hailing. Kazakhstan will serve as the first test market. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261023143469/en/ inDrive partners with Pony.ai and NVIDIA to explore autonomous mobility in Kazakhstan Kazakhstan was chosen first for its regulatory readiness following the creation of the country’s first structured legal framework for driverless transport, as part of its “Year of Digitalization and Artificial Intelligence.” Combined with Kazakhstan’s position as a leading Central Asian economy, this gives the companies a clear basis to assess autonomous ride-hailing in practice. The three companies will evaluate the technical, operational, regulatory and

Brenus Pharma's Novel In Vivo Immunotherapy STC-1010 Shows Safety, Activating T Cells in First-Line MSS Metastatic Colorectal Cancers With 2 Complete Responses.23.10.2026 15:50:00 EEST | Press release

Brenus Pharma, a clinical-stage biotech company, announced first data from the Phase Ia dose escalation of BreAK CRC-001. Nine unresectable patients were treated; 89% had liver metastases and 89% KRAS-mutant tumors, a population refractory to immunotherapy. Median follow-up: 8 months (1–14; data cut-off 6/08/2026). 95% of metastatic colorectal cancers are pMMR/MSS tumors, poorly immunogenic and resistant to immunotherapy. STC-1010, the company’s lead in vivo DC-engager, is designed to make these “cold” tumors visible to immune cells. Safety: no dose-limiting toxicity, only grade 1–2 related adverse events. Clinical activity (seven evaluable patients, RECIST 1.1): 100% disease control, 57% objective response rate (4/7). 43% of patients became operable (3/7): two with no evidence of disease afterward. Molecular profile: ctDNA dropped by up to 97% within two months, TP53 and KRAS mutations near undetectable. Immune activity (first six patients): STC-1010 regimen nearly quadrupled cytotoxi

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye